Recombinant Human TNF-β

Recombinant Human TNFβ (also known as lymphotoxinalpha, LTα) is used in research applications to study its roles in inflammation, immune regulation, lymphoid organ development, and cytotoxicity against tumor cells.

Key reasons to use Recombinant Human TNFβ in research:

• Modeling Inflammatory and Immune Responses: TNFβ is a potent mediator of inflammatory and immune responses, acting through TNF receptors (TNFR1 and TNFR2) to regulate immune cell activation, cytokine production, and cell death pathways.
• Lymphoid Organogenesis: TNFβ is essential for the development and organization of secondary lymphoid organs, such as lymph nodes and Peyer’s patches, making it valuable for developmental immunology studies.
• Tumor Cytotoxicity: Like TNFα, TNFβ can induce cytotoxic effects on certain tumor cells, supporting research into cancer biology and potential antitumor therapies.
• Autoimmunity and Demyelination Models: TNFβ is implicated in autoimmune disorders and inflammatory demyelination, making it relevant for studying diseases such as multiple sclerosis and rheumatoid arthritis.
• Bioassays and Functional Studies: Recombinant TNFβ is used in cellbased assays to assess cytokine signaling, cytotoxicity, and immune cell function, providing a controlled and reproducible reagent for mechanistic studies.

Additional considerations:

• Recombinant proteins offer high purity, batchtobatch consistency, and defined activity, which are critical for reproducible experimental results.
• Using human recombinant TNFβ ensures species specificity, which is important for translational research and human cellbased assays.

In summary, Recombinant Human TNFβ is a versatile tool for dissecting the molecular and cellular mechanisms of inflammation, immunity, lymphoid tissue development, and tumor biology in both basic and translational research contexts.

Recombinant Human TNFβ can be used as a standard for quantification or calibration in ELISA assays, provided it is properly validated for your specific assay system.

Most commercial ELISA kits for human TNFβ (also known as lymphotoxinalpha) are designed to recognize both natural and recombinant forms of the protein, and they typically use recombinant TNFβ as the calibration standard for generating the standard curve. This allows for accurate quantification of TNFβ in biological samples by comparing sample signals to those generated by known concentrations of the recombinant standard.

Key considerations for using recombinant TNFβ as an ELISA standard:

• Parallelism: The assay should demonstrate parallel doseresponse curves between the recombinant standard and endogenous TNFβ in your sample matrix. This ensures that the antibodies in the kit recognize both forms equivalently, allowing for accurate quantification.
• Standard Preparation: Prepare the recombinant TNFβ standard according to the manufacturer’s instructions, typically by serial dilution in the same buffer used for your samples to minimize matrix effects.
• Validation: If you are developing your own ELISA or modifying a commercial kit, validate that your recombinant TNFβ standard produces a linear and reproducible standard curve within the assay’s dynamic range.
• Formulation: Recombinant TNFβ is often supplied lyophilized and may contain carrier proteins such as BSA to enhance stability. Reconstitute and store the standard as recommended to maintain activity and consistency.

Best practices:

• Always run a fresh standard curve with each assay batch to account for potential variability in protein stability or assay conditions.
• Confirm that your recombinant TNFβ is of high purity and correctly folded, as misfolded or degraded protein may not be recognized by the ELISA antibodies.
• If available, correlate your standard to an international reference standard (e.g., NIBSC/WHO) for greater comparability across studies.

In summary, recombinant human TNFβ is widely accepted and routinely used as a standard for ELISA quantification, provided the assay is validated for parallel recognition of recombinant and natural protein forms.

Recombinant Human TNFβ (Lymphotoxinα) has been validated for a range of applications in published research, primarily in bioassays, cellbased functional studies, and various immunological and inflammationrelated assays.

Key validated applications include:

• Bioassays for cytotoxicity: TNFβ induces cytotoxicity in cell lines such as L929 mouse fibroblasts, especially in the presence of actinomycin D, serving as a standard assay for TNFβ activity.
• Cell signaling and receptor activation studies: TNFβ homotrimers activate TNF receptors (TNFRSF1A, TNFRSF1B, HVEM/TNFRSF14), and heterotrimers with LTβ activate LTβR/TNFRSF3, making it useful for dissecting receptormediated signaling pathways.
• Immunological research: TNFβ is used to study lymph node development, inflammation, autoimmune disease mechanisms, and immune cell regulation, including dendritic cell and NK cell interactions.
• Inflammation and autoimmune disease models: TNFβ has been applied in models of inflammatory demyelination, rheumatoid arthritis, lupus, and other autoimmune conditions.
• Cancer research: TNFβ is used to investigate its role in cell proliferation, apoptosis, and tumor microenvironment modulation.
• Leukocyte transmigration and vascular biology: TNFβ has been used to study mechanisms of leukocyte movement across endothelial barriers in inflammation.
• Antibody and inhibitor validation: Recombinant TNFβ is employed in binding and neutralization assays to validate therapeutic antibodies and nanobodies targeting TNF pathways.
• Protein detection and quantification: TNFβ is used as a standard in ELISA, Western blot, immunoprecipitation, flow cytometry, and immunofluorescence protocols for protein quantification and localization.

Summary Table of Validated Applications

Additional Notes:

• TNFβ is frequently used in whole cell assays and in vitro systems, but also in animal models for mechanistic studies.
• Its role in mediating inflammatory and immune responses makes it a standard reagent for validating new therapeutics and studying disease mechanisms.

If you require protocol details or specific assay conditions for any application, please specify the intended use.

To reconstitute and prepare Recombinant Human TNFβ (Lymphotoxinalpha) for cell culture experiments, dissolve the lyophilized protein at a concentration of 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin (BSA). This carrier protein helps stabilize TNFβ and prevents adsorption to plasticware.

Stepbystep protocol:

• Equilibrate the vial and reconstitution buffer (PBS + 0.1% BSA) to room temperature before opening.
• Centrifuge the vial briefly to collect the lyophilized powder at the bottom.
• Add buffer: For example, to reconstitute 10 μg of protein, add 100 μL of sterile PBS with 0.1% BSA to achieve 100 μg/mL.
• Gently mix by pipetting or swirling; avoid vigorous vortexing to prevent protein denaturation.
• Incubate at room temperature for 15–30 minutes to ensure complete dissolution. If visible flakes remain, continue gentle mixing for up to 2 hours.
• Aliquot the reconstituted solution into working volumes to avoid repeated freezethaw cycles.
• Storage: Store aliquots at ≤ –20°C for longterm use. For shortterm use (up to 1 week), store at 2–8°C. Avoid repeated freezethaw cycles.

Preparation for cell culture:

• Dilute the stock solution to the desired working concentration using cell culture medium containing a carrier protein (e.g., 0.1% BSA or heatinactivated FCS) to minimize adsorption and loss.
• Determine optimal concentration for your specific assay by performing a doseresponse experiment, as effective concentrations may vary (e.g., ED50 for TNFβ bioactivity is typically 0.1–0.4 ng/mL).
• Sterility: Ensure all solutions and containers are sterile to prevent contamination.

Additional notes:

• If the protein is supplied carrierfree, reconstitute in sterile distilled water to 0.1–1.0 mg/mL, then dilute in buffered solution with carrier protein for cell culture.
• Always consult the productspecific Certificate of Analysis (CoA) or datasheet for any unique instructions.
• Avoid sodium azide in functional assays, as it can be cytotoxic.

Summary Table:

This protocol ensures maximum stability and bioactivity of recombinant TNFβ for cell culture applications.